|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-12-31
|
|
pubmed:abstractText |
To determine the maximum tolerated dose (MTD) of erlotinib when administered concurrently with twice weekly gemcitabine and radiation therapy (RT) for locally advanced pancreatic cancer, assess the safety and toxicity profile of this combination and secondarily evaluate response, time to tumor progression and overall survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
86-91
|
|
pubmed:meshHeading |
pubmed-meshheading:17878176-Adenocarcinoma,
pubmed-meshheading:17878176-Adult,
pubmed-meshheading:17878176-Aged,
pubmed-meshheading:17878176-Antimetabolites, Antineoplastic,
pubmed-meshheading:17878176-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17878176-Combined Modality Therapy,
pubmed-meshheading:17878176-Deoxycytidine,
pubmed-meshheading:17878176-Disease Progression,
pubmed-meshheading:17878176-Female,
pubmed-meshheading:17878176-Humans,
pubmed-meshheading:17878176-Male,
pubmed-meshheading:17878176-Maximum Tolerated Dose,
pubmed-meshheading:17878176-Middle Aged,
pubmed-meshheading:17878176-Neutropenia,
pubmed-meshheading:17878176-Pancreatic Neoplasms,
pubmed-meshheading:17878176-Protein Kinase Inhibitors,
pubmed-meshheading:17878176-Quinazolines,
pubmed-meshheading:17878176-Radiotherapy, Adjuvant,
pubmed-meshheading:17878176-Survival Analysis,
pubmed-meshheading:17878176-Thrombocytopenia,
pubmed-meshheading:17878176-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
|
|
pubmed:affiliation |
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
